ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a severely debilitating disease characterized by progressive degeneration of motor neurons. Charcot first described ALS in 1869 1
Is there an immune component to the pathology of amyotrophic lateral sclerosis (ALS)? At the most basic level, there are 3 possibilities: inflammation and immunity (a) have a direct role in causing ALS, (b) affect the progression of disease, or (c) are not directly involved in the disease. In this review, we critically evaluate reports investigating inflammation and the immune system in ALS pathogenesis. The data provide tantalizing clues that immune system components may indeed play a role in ALS pathogenesis, but results suggesting a causative or significant role in disease remain limited.
INFLAMMATION, IMMUNOLOGYM AND ALS
For neurodegenerative diseases such as ALS an interesting question is why specific cell populations or brain regions (e.g., motor neurons in ALS or dopamine-producing cells in the substantia nigra in Parkinson's disease) are targeted. Uncovering these potential reasons may provide important clues to disease mechanisms and lay a foundation for effective therapeutic strategies. There are several hypotheses for the underlying causes of or contributors to ALS. These include glutamate toxicity, increased reactive nitrogen and oxygen species (ROS), and subsequent free radical damage, protein aggregation and disruptions in proteostasis, defects in RNA processing and endoplasmic reticulum (ER) stress and mitochondrial dysfunction, axonal transport dysfunction, environmental toxins, viral infections, and insufficient availability of trophic factors. [1] [2] [3] Although there is little doubt that these mechanisms are involved at some point in disease pathogenesis, none account for the specific destruction of motor neurons in ALS.
A question can be raised as to whether ALS is a disease specific to motor neurons. Indeed, it is well established that ALS is not cell-autonomous. Multiple cell types, such as Schwann cells, astrocytes, oligodendrocytes, and microglia are involved in pathogenesis, however investigations of earliest pathology in animal models reports changes specific to motor neurons suggesting that these are the first cells affected. 4, 5 There are several mechanisms that may account for the selective targeting of a specific molecular or cellular population: genetics, prion, viruses, and/or the immune system. Although genetic mutations/polymorphisms are associated with ALS and are expressed in many cell types, it remains unclear why motor neurons and/or other neuronal populations are targeted. Interestingly, there is genetic overlap between ALS and frontotemporal dementia (FTD) that further demonstrates non-cell autonomy. Recent discoveries identified genetic mutations in open reading frame 72 on chromosome 9 (C9orf72), the most common genetic variants associated with ALS and FTD, resulting in hundreds to thousands of GGGGCC hexanucleotide repeats that may lead to a decrease in the protein's expression in cells. 6 In animal models, specific deletion of C9orf72 from myeloid cells in mice (specifically macrophages and microglia) resulted in lysosomal accumulation, hyperactive immune responses, and increased expression of cytokines interleukin (IL)-6 and IL-1β, 6, 7 altering the normal immune function of these cells. It is still unclear whether these results can translate to human patients, but the findings present the possibility of altered systemic immunity playing an active role in the disease. 8 Further, some genetic mutations, such as those with superoxide dismutase 1 (SOD1), result in a prionlike protein [9] [10] [11] and localization of these proteins may accumulate uniquely in motor neurons. 12 Interest in a possible viral cause of ALS has not been supported, as no viral particles could be detected in ALS patients/ tissue and treatment with the antiviral agent interferon-gamma actually promoted progression of the disease. 13 More modern sensitive polymerase chain reaction (PCR) techniques were used in one study to identify enteroviral transcripts in spinal cord tissue from 86% of the ALS patients examined, as compared with 3.4% of a control sample 14 ; however, a subsequent report failed to confirm these results. 15 In either case, as reverse transcriptase-PCR was necessary to detect the transcript in the work by Berger and colleagues, the low quantity of viral material indicates that ALS is most likely not the result of a recent, active, or chronic viral infection. An ALS-like syndrome also has been demonstrated in some patients with HIV infection. It is hypothesized that motor neuron (MN) degeneration in these patients is due to activation of human endogenous retrovirus K by the Tat protein of HIV, 16, 17 which has shown to be cytotoxic when expressed in neurons, thus providing further evidence that ALS is not a virus-associated disease.
The specificity of the immune system could also precipitate selective motor neuron destruction in ALS. In fact, the specificity of the immune system has been used as a tool to identify individual molecules that are expressed specifically in functionally related neurons (e.g., limbic system-associated membrane protein [18] [19] [20] . Antibodies can be generated specifically to toxic forms of proteins while not recognizing native protein and, importantly, these antibodies may have therapeutic value because vaccination with mutant protein proved beneficial in animal models. [21] [22] [23] Potential autoimmune activity has been repeatedly described in ALS patients, [24] [25] [26] [27] [28] as have elevations in global inflammatory responses, such as increases in circulating neutrophils. 29 At this point, it is necessary to consider differences between "inflammation" and "immune response." Inflammation (also referred to as innate immunity) and acquired immunity (often referred to as the immune response) are responses along a continuum. Inflammation is often the primary response to infection or injury. It is characterized by the cellular accumulation of resident cells such as tissue phagocytic cells, known as macrophages, and circulating neutrophils and monocytes that engulf infectious agents/cells. The response is often limited with the goal of isolating sites of injury and infections from healthy tissues. However, there are pro-and anti-inflammatory components with expression that serves to enhance or dampen the response. The adaptive immune response has a longer duration, involves a complex orchestration of cellular and molecular responses, and is generated to a specific pathogen or antigen with a presence that may not have been resolved by the inflammatory response. Cells associated with this response also include tissue macrophages (referred to as microglia in the nervous system) that can serve as antigen-presenting cells, B cells that mature into antibody-producing cells, and T cells with subsets that are critical to cellular immunity. The orchestrated immune response may further contribute to inflammation that can then enhance additional immune system involvement.
With this in mind, if there is a critical role for the immune system in at least a variant of ALS, then a subset of patients would exhibit some combination of the following factors: an association with specific human leukocyte antigen (HLA) major histocompatibility complex (MHC) class I and II phenotypes, specific autoantibodies in serum and/or cerebrospinal fluid (CSF), and presence of immune-competent cells such antigen-presenting cells (e.g., tissue macrophages in peripheral muscles and nerves or microglia in the central nervous system [CNS] ) and/or effector B and T cells at sites of pathology. Furthermore, as motor neurons span both peripheral and CNS environments, the presence of immune-competent cells could then be found in one or both arenas. The timing of responses is also important to consider. For example, in animal models of the disease, the genetic alteration, such as overexpression of mutant SOD1, precipitates motor neuron dysfunction and subsequent degeneration. Inflammatory and immune responses observed in these models may well contribute to disease progression, but are unlikely to be the trigger for the MN dysfunction. A thorough characterization in animal models and patients using modern approaches, such as to when, where, and the extent to which immune system responses are mounted in relationship to disease pathology, will provide a better understanding of whether the immune involvement is a critical component of disease progression and a viable target for intervention.
Further, it is unknown whether a subset of ALS patients manifest disease through autoimmunity, and characterization of HLA phenotypes and presence of disease-specific antibodies or cell populations must be identified before valid conclusions can be drawn.
NEUROINFLAMMATION AND MICROGLIA
Tissue damage and infection are key triggers for inflammatory responses, with neutrophils, circulating monocytes, and tissue macrophages serving as first responders. These cells are critical for limiting the spread of damage and, if contained, limit initiation of adaptive immune responses involving B and T cells that produce antibodies and cytokines. In ALS, extensive research has characterized "neuroinflammation" or glial activation. [30] [31] [32] [33] "Neuroinflammation" is a key characteristic of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and ALS. Microglia are critical participants in neuroinflammation; however, what are the specific roles of microglia and their peripheral tissue macrophage counterparts in disease? Microglia in the CNS or macrophages in muscle are capable of functioning as antigen-presenting cells to initiate immune responses. Another critical function concerns tissue homeostasis, notably resolving cellular debris that results from degenerating presynaptic terminals at neuromuscular junctions, degenerating peripheral axons, or cellular debris in the spinal cord from the frank degeneration of motor neuron (MN) cell bodies and dendrites. 34, 35 Early in disease, muscle macrophages may respond to initial neuromuscular junction (NMJ) denervation, possibly phagocytizing presynaptic terminals. With NMJ denervation, microglia in the CNS may also respond with synaptic stripping of MN soma and dendrites in the spinal cord. 36 It is critical to determine when activation is observed and to correlate it with known pathologic events. In addition, are these responses resolved, or does the phagocytized debris serve as antigen to stimulate immune system activation?
Markers for microglia such as leukocyte common antigen (LCA; also known as CD45 or protein tyrosine phosphatase receptor type C [PTPRC]), CD11b (cluster of differentiation 11b or integrin alpha M [ITGAM]), ionized calcium-binding protein 1 (IBA1), and CD68 (also known as GP110, macrosialin, scavenger receptor class D, LAMP4, and ED1) are clearly and consistently upregulated in the spinal cord of transgenic mice and in ALS patient tissue. 24, 37 In addition, the p.R47H variant of the microgliaactivating gene, TREM2, was more commonly expressed in ALS patients compared with healthy controls, and spinal cord expression of this variant correlated negatively with patient survival. 38 The study of postmortem tissue from ALS patients has provided evidence of microgliosis in all areas of expected disease pathology, including motor cortex, motor nuclei of the brainstem, along the corticospinal tract, and in the ventral horn. 24, 39 The use of positron emission tomography (PET) imaging coupled with proteins expressed by activated microglia has allowed for the visualization of active gliosis in humans in vivo and has demonstrated widespread microglial activation in the motor cortex, dorsolateral prefrontal cortex, and thalamus. 40 Importantly, increased microglial activation in the motor cortex corresponds to more severe clinical upper motor neuron (UMN) scores in ALS. 40 Another study also demonstrated microgliosis in the bilateral motor cortices and corticospinal tracts compared to healthy controls. 41 Increased microgliosis in the precentral gyrus correlated positively with UMN scores and negatively with ALS Functional Rating Scale (ALSFRS) scores, 41 thus further demonstrating the positive relationship between neuroinflammation and disease severity. To better investigate activation of microglia and correlate this with muscle denervation and MN degeneration, we now turn to animal models.
The SOD1 G93A mouse was the first mouse model developed after the identification of mutations in the SOD1 gene in a subset of familial ALS patients in 1993 42 and, accordingly, the foundation of our knowledge of the etiology and pathogenesis of the disease comes from studies carried out using this animal model. 43 Although many preclinical trials in ALS have failed to translate to the clinic, 44 carefully planned and executed experiments remain more feasible and efficient in mouse models, provided experiments are conducted not in terms of whether the mouse survives longer, but rather to determine what aspects of disease pathology are altered with therapeutic intervention and if that pathology is clinically relevant 4, 5 ( Fig. 1 ). One could argue that the model has only taught us about SOD1-mediated pathology, but thorough characterization of the more recently developed models (e.g., TDP-43, Fus, and C9orf72 mouse models) and comparison to the SOD1 mouse and each other will allow us to determine common pathology. For example, although mostly studied in the SOD1 mouse models, microglial activation is also reported in other models of genetic ALS, including C9orf72. 45 However, as noted earlier, a caveat with the use of animal models is that potential changes in the immune system, or other systems, may be independent of MN disease pathology, and rather are direct results of deletion or overexpression of mutant proteins that influence immune function when expressed in these cells. [46] [47] [48] [49] With the advent and incorporation of more sensitive motor assessment approaches, it is now well established that disease begins in the SOD1 G93A mouse model of ALS at approximately the first postnatal month, much earlier than originally appreciated. 4 Furthermore, glial activation is observed at these "early" time-points. [50] [51] [52] [53] Microglial activation has also been reported in the SOD1
G93A rat model at "preclinical" stages. 54 Results from experiments utilizing cell-specific deletion of mSOD1 via a Cre/Lox approach suggest that mutant mSOD1 (mSOD1) expression in MNs is important in determining timing of disease onset and early progression, but expression in non-neuronal cells, such as immune and inflammatory cells, can influence disease severity and progression. 55, 56 Indeed, when mutant SOD1 is deleted from microglia, disease onset is not affected, but disease progression is prolonged. These results further suggest MNs as a site of onset, but with glial responses significantly contributing to disease progression.
In the CNS, under physiological conditions, microglia display an apparent "homeostatic," "inactivated,"
or "resting" phenotype, with small cell bodies and large ramified processes; however, despite the descriptive terms, these cells are constantly active, surveying the CNS microenvironment and secreting factors that allow for close interaction with astrocytes and neurons. Distinct microglial phenotypes, as characterized by size, shape, and antigen expression, appear to respond to injury of the early postnatal vs. adult brain, 57, 58 and it is not known whether the phenotypes or state of activation of microglia that respond with synaptic stripping to nerve axotomy 59, 60 are the same as the response to neuronal injury and death. 61 Microglial expression of antigens, receptors, cytokines, and trophic factors is complex and the response or contribution to ALS pathogenesis suggests a complicated interconnectivity with other pathogenic cells and cellular responses. 62 There appear to be at least 3 phenotypes to "activated" macrophages (classically lipopolysaccharide FIGURE 1. Summary of pathological events in the mutant SOD1 mouse model of ALS. Events are shown as reported in high-expressing SOD1G93A mice for the CNS, peripheral axons, and muscles, and corresponding behavioral changes. Earliest changes are documented at left, before day 30. Changes documented in the space between MNs correspond to time-points between the dates listed above the MNs. Although disease progression varies based on expression of mutant protein with disease onset and end-stage occurring at later dates, similar sequences are expected in other models of mutant SOD1. M, microglia; A, astrocyte; M1, activated (M1) microglia; MF, macrophage. Early and middle disease gaps in axons distinguish CNS from peripheral events.
[LPS], alternatively or M2, and the M1s), with each phenotype being induced by distinct stimuli, although many markers are shared by both classically activated, and M1 phenotypes. [63] [64] [65] Because LPS-induced classically activated macrophages are considered exclusively experimental, many studies have considered activated microglial phenotypes to be broadly classified into 2 subsets: M1 or M2. M1 macrophages (including microglia) are largely pro-inflammatory and secrete a number of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and interleukin-1beta (IL-1β), as well as upregulating oxidative metabolites, such as nitric oxide (NO). In contrast, M2 macrophages are thought to be largely anti-inflammatory and respond to and release trophic and anti-inflammatory factors such as IL-4, IL-13, and IL-10, which aid in resolution of the immune response. Thus, macrophages can mount distinct pro-and anti-inflammatory functional responses depending on their intrinsic properties, interaction with cellular microenvironment, and the presence of pathogenic factors.
Several studies have proposed the presence of M1 and M2 microglia in ALS, with M2 possibly switching to an M1 phenotype with disease progression. 66, 67 However, strict dichotomous characterization of microglia and macrophages as either M1 or M2 is not appropriate as these cells are capable of transitioning between phenotypes depending on environmental context, with tissue macrophages often developing mixed phenotypes in pathological contexts. 68 One study investigating the role of microglia in inducing MN degeneration reported enhanced activation of microglia of a M1 phenotype, but did not observe any change in M2 markers. 69 Although the study also demonstrated that selective deletion of nuclear factor-kappaB (NF-κB) signaling in microglia is capable of rescuing motor neurons from microglia-mediated death in vitro, and is capable of delaying disease progression by a considerable amount in SOD1 mice, it is unclear whether these responses are translatable to human patients, are ALS specific, or if deletion of NF-κB simply renders microglia incapable of reacting to degenerating cells. The majority of studies in vivo have focused more on end-stage effects, where microglia may indeed induce the physical degeneration and removal of MNs, but do not appear to initiate NMJ denervation and initial MN dysfunction (see Figs. 1 and 2) .
The majority of studies in ALS, as with other models of disease and injury, have relied on in-vitro analysis and/or Northern or Western blot analyses. Unfortunately, these approaches cannot determine localization of individual phenotypes within tissue such as spinal cord, nerve, or muscle. Furthermore, when examined in mouse models, many studies focused on later stages of disease where robust glial activation is prominent. Consequently, it is impossible to distinguish whether microglial activation is contributing to MN degeneration, or is resulting from signals (mutant SOD1 protein, TDP-43 aggregates, or other degeneration related proteins) being released by dying MNs. 48, [70] [71] [72] [73] Therefore, involvement of specific microglial phenotypes remains to be documented in situ in disease-affected tissue, and association with specific pathological events, other than end-stage MN degeneration in ALS, remains to be determined.
Astrocytes as Immune Mediators. Astrocyte activation has been well characterized in ALS and other neurodegenerative diseases. [30] [31] [32] [74] [75] [76] [77] Like microglia, astrocytes can promote neuronal survival through secretion of trophic factors, nutrient regulation, and control of excitatory amino acids. In disease, astrocytes may also adopt a potentially toxic role contributing to disease pathology. Recent work has further suggested that microglial release of inflammatory factors serves as a trigger for activated neurotoxic astrocytes. 78 Yet, although astrocytes may prove to be a therapeutic target in ALS, 79 the specific role of astrocytes in ALS does not appear to be associated with initiating or regulating an immune response, but rather further contributing to MN dysfunction and degeneration. Astrocyte toxicity appears to promote downregulation of MHC class I proteins in MNs, which in turn may make the MNs more susceptible to astrocyte toxicity. 80 Peripheral Monocytes/Macrophages. Assessment of circulating monocytes has been performed to gain insight into potential inflammatory or immune system activation in ALS and other neurodegenerative diseases. 81, 82 The rate of disease progression in ALS has been suggested to be related to the degree of systemic monocyte/macrophage activation. 81 Although ALS patient monocytes exhibit an RNA profile suggesting an "activated" phenotype, corresponding levels of cytokines could not be measured. 82 It is tempting to conclude there is a role for systemic immune activation in ALS disease progression, but one cannot dismiss alternative causes of immune system activation that are associated with indirect consequences of disease progression. For example, chronic hypoxia in ALS patients has been reported to be associated with elevated IL-6 levels. 83 Further, although speculative, lung damage secondary to loss of innervation of diaphragm and decreased respiratory function, or aspiration secondary to loss of bulbar function, may leave the patient susceptible to subtle changes in cellular environment or low-level, subclinical infections that result in increased cytokine production and other immune responses in ALS patients. Reports suggest 2%-10% of the global population presents with subclinical infections, and that the vast majority of influenza infections are subclinical. 84, 85 A more thorough clinical characterization of subjects would greatly improve investigator ability to better interpret findings.
Muscle and peripheral nerves are integral sites of ALS pathology involving loss of presynaptic terminals, Schwann cell and myelin disruption, and axonal degeneration. Undoubtedly, tissue macrophages respond, yet this has not been investigated in ALS patients. Again, animal models are more amenable to this research.
Disease begins in the SOD1 G93A mouse model of ALS at approximately the first postnatal month with the loss of MN connection to the muscle at the NMJ. 4, 5, [86] [87] [88] [89] However, a potential role of macrophages and the immune system in this early pathology in muscle has not been investigated. Later, at p60, peripheral macrophages are detectable along degenerating nerve fibers in ventral roots, sciatic nerves, and intramuscular axons of ALS mice and continue to an increase in number through the endstage of disease. 90 Monocyte chemoattractant protein-1 (MCP-1), IgG, IgM, and complement deposition are detected in sciatic nerves concomitant with macrophage accumulation, thus demonstrating signaling by which macrophages could be recruited to degenerating peripheral nerves in ALS. 90 Activated macrophages have been reported surrounding NMJs in symptomatic and end-stage mouse and rat models. 91, 92 The response of macrophages in peripheral nerve and muscle in ALS animals models may not be unique to ALS as similar results have long been established in other models of peripheral nerve injury. 93 Interestingly, it remains to be determined whether macrophages are neuroprotective and promote nerve regeneration or serve only to remove degenerating axons and myelin.
Complement factors appear to play a role in recruiting macrophages to denervated muscle. 90, 94, 95 Macrophage expression of terminal complement system C5a's receptor (C5aR1) appears critical as loss of this receptor results in reduced macrophage activation and may influence NMJ denervation. 95 Importantly, after removing cellular debris, activated macrophages are capable of presenting antigens from this debris, thus stimulating further immune responses, although whether this actually occurs in ALS remains to be explored. The role of peripheral immune and inflammatory mechanisms associated with NMJ denervation in ALS warrants further study.
T and B Cells in ALS.
Autoimmune disorders occur when a loss of immune regulation occurs such that "self" antigens are recognized as foreign. Molecular mimicry (activation of autoreactive T cells by bacterial or viral agents that have antigens similar to self antigens), viral superantigens (activation of autoreactive T cells that express particular Vβ segments), bystander activation (expansion of previously activated T cells at an inflammatory site), and enhanced processing and presentation of autoantigens, leading to priming of autoreactive lymphocytes, are all examples of induction of autoimmunity by infectious agents. 96 FIGURE 2. Throughout disease progression, inflammation levels may vary between low and high depending on pathological events. Initial NMJ denervation may prime CNS microglia for a low inflammatory state (1). As disease progresses, atrophying muscles will release pro-inflammatory cytokines into systemic circulation that can activate circulating monocytes and lymphocytes (2) . Depending on the T cell's differentiated state, (3) Treg cells dampen the activation of other innate immune cells or (3) Th1 and/or Th17 cells act with mutual positive feedback to enhance their own activation and the activation of other circulating innate immune cells. Motor neuron degeneration in the CNS activates microglia (4) . Disruptions in the blood-brain barrier allow activated immune cells from the periphery to cross into the CNS in response to chemotactic signals where they (5, 6) act in mutual positive feedback with activated microglia to further enhance inflammation and (7) release pro-inflammatory cytokines to propagate the response.
Thus, expansions of specific B-and/or T-cell populations are hallmarks of autoimmune disorders. Well-characterized examples include autoantibodies to 2 islet cell antigens, glutamatic acid decarboxylase and islet antigen-2 in type 1 diabetes, the aceytylcholine receptor in myasthenia gravis, and presence of oligoclonal bands as a clinical diagnostic for MS. [97] [98] [99] The expansion of specific Vβ2-T-cell receptor cells in ALS patients as compared with material from controls (including both patients who died from neurological diseases and those who did not) has been reported. 100 These data would then support the involvement of a specific T-cell population in a subset of ALS patients, but does not likely reflect a general autoimmune component in disease progression such as that seen in models of myasthenia gravis. 101 A switch from general inflammatory responses (innate immunity) to a refined, adaptive immune response is characterized by the appearance of circulating lymphocytes (B and T cells 103 Through interaction with Fas (CD95) expressed on host cells, cytotoxic T cells activate downstream caspases and initiate apoptosis of host cells, whereas release of perforin facilitates pore formation in target cells through which granzymes enter and activate apoptotic pathways. Helper T cells (CD4 + ; Th) function to influence the activity of other cell types involved in the immune response, such as microglia/macrophages, B cells, and antibody production. 104 Th can be further divided into subsets based on cytokine production and precise function. Th1 and Th17 cells release pro-immune and inflammatory mediators and promote further responses, including additional activation of macrophages, T-cell expansion, and IgG antibody responses. Conversely, Th2 cells release anti-immune and anti-inflammatory cytokines, such as IL-4, which limit responses. Another subset of the Th lymphocyte are regulatory T cells (Tregs), characterized by expression of the transcription factor FoxP3, which act to regulate the nature and extent of immune activation. 105 Systemic alterations in T-cell populations have been reported in ALS patients with contradictory results. For example, decreases in circulating CD4 + cells and increases in IgG levels have been reported in ALS patients when compared with healthy controls. 106 Interestingly, patients with higher ALSFRS-R scores (i.e., better function) exhibited the greatest changes. These results could suggest that the decrease in circulating T cells early in the disease reflects increases in these cells at the site of pathology, although confirmation of this hypothesis remains to be determined. Conversely, in another study, ALS patients exhibited increases in circulating CD4 + cells when compared with healthy controls. 81 In the study, although increases in T cells were observed, activation of the cells was decreased in ALS patients and was more severe in patients with lower ALSFRS-R scores (i.e., more progression). A third study reported increases in CD4 + with decreases in CD8 + and Tregs (CD4 + /CD25 + ) in ALS patients when compared with healthy controls. 107 In the study, significant changes were reported in patients at less severe stages of disease. The lack of consistent results across studies confounds interpretations as to whether levels of circulating T cells are indicative of disease-specific immune responses in ALS.
As Treg cells are critical to mediating T-cell responses in general, they have also been studied in ALS. The number of Tregs and characteristic transcription factor FoxP3 expression were significantly decreased in more rapidly progressing patients and inversely correlated with rate of disease progression. 108 Furthermore, levels of transforming growth factor-beta (TGF-β), IL-4, and Gata3, a transcription factor characteristic of Th2 cells, were also detected in rapidly progressing patients and inversely correlated with rate of progression. 108 This effect of Tregs on survival appears to be mediated by loss of function rather than decrease in number. 109 Although dysfunctional Tregs (with both slow and rapid progression) were present in all ALS patients, greater Treg dysfunction was associated with a higher clinical disease burden and a more rapid progression. 109 Disruption in immune system function may indeed contribute to more rapid disease progression; however, it has not been confirmed whether this occurs as part of the disease process itself, or whether its is due to secondary opportunistic infections, which have risk and number increasing with disease progression. Circulating monocytes and lymphocytes are exquisitely sensitive to stimulation, including those that occur with delays in processing cells after blood collection and changes in pH, temperature, and overall experimental conditions, which may vary between laboratories. As such, to interpret results from patients and healthy controls, investigators must maintain the strictest and most consistent conditions to be able to compare one sample to the next.
To further understand the specific role of T cells in ALS pathogenesis, investigators have turned to the mutant SOD1 mouse model. In SOD1 mice, CD4 + T cells are also observed in the lumbar spinal cords late in the disease. 71, [110] [111] [112] The results are consistent with findings of T-cell infiltrates in postmortem tissue of ALS patients. Interestingly, although occasional cells may be present earlier, a robust presence of T cells in SOD1 mice appears later in disease, well after the onset of gross motor deficits and multiple pathological events (e.g., NMJ deneration, glial activation, and blood-brain barrier disruption; see Fig. 1 ). Further, although loss of T cells has been associated with worse outcome, disease onset itself does not change. The appearance of CD4 + T cells later in the disease may be associated with a corresponding stabilization of disease progression and expression of potentially neuroprotective factors such as insulinlike growth factor-1 (IGF-1). 111, 112 However, at this point, MN degeneration is well underway in this model, and the protective effect of Th cells may be to limit activation of microglia and/or astrocytes from expanding to toxic levels and altered phenotypes. 113 In SOD1 mice lacking mature B and T cells (mSOD1/RAG2 -/-), end-stage microglial activation is reduced and disease progression is enhanced as compared with SOD1 mice with mature lymphocytes (mSOD1/RAG2 +/− ). Bone marrow transplantation of wild-type CD4 + T cells into mSOD1/RAG2 -/-mice was found to extend survival and restore microglial activation. 111 Nonetheless, survival is not as long as in mSOD1 mice with a complete repertoire of lymphocytes. Together, these results suggest a potential role for T cells in disease progression; however, they may also indicate yet-tobe-investigated secondary symptoms associated with decreased pulmonary function or incidental infections. Indeed, in the SOD1 mouse, detection of Tcell cytokines is limited, even at the end-stage of the disease, further suggesting that these cells play a minor role in disease pathology in the mouse model.
ANTIBODIES IN ALS
Increased concentrations of specific antibodies suggests an expansion of specific B-cell population(s). ALS patients exhibit increased serum immunoglobulin concentrations when compared with control subjects. 114 Antibodies to GM1 have been reported in ALS patients. 115 However, anti-GM1 antibodies are also found in individuals with multifocal MN neuropathies, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy, 116 and may reflect an immune response to degenerating or damaged neurons as these glycolipids may become available as antigens in cell injury and death. Antibodies to calcium channels have been reported, 26 but it is unclear whether these antibodies are to the calcium channels on muscle or MNs. 117, 118 Furthermore, several other studies have failed to identify the presence of antibodies to calcium channels in the sera of ALS patients. 119 In addition, antibodies to Fas 120, 121 and lipoprotein-related protein 4 (LRP4) 122 -a membrane protein crucial in the development and function of NMJs-have been reported in the sera of ALS patients. Although the existence of autoantibodies is often indicative of autoimmune disorders, antibodies to GM1, calcium channel subunits, Fas, and LRP4 may not account for the specific destruction of MNs in ALS, as they are also generated in other neurodegenerative disorders. Indeed, the functional role of these autoantibodies in ALS is still speculative, but they may be a driving factor in the disease progression of a limited population of ALS patients even if they do not contribute to a majority of cases.
HLA ASSOCIATIONS IN ALS
As with other autoimmune disorders, an autoimmune component to ALS would be indicated by a predominant HLA or MHC phenotype in at least a subpopulation of ALS patients. HLA class I and II molecules are cell surface proteins that distinguish self from non-self. Although class I molecules are expressed by all nucleated cells, class II molecules are expressed on antigen-presenting cells and are critical for initiation of immune responses. There are 3 class I genes (A, B, and C) that code for the transplantation antigens. The class II genes are DP, DQ, DR, and DZ.
Several studies have reported HLA associations in ALS patient populations; however, many of the results were contradictory and the majority of reports were performed during the late 1970s to mid-1980s, [123] [124] [125] [126] [127] [128] before the availability of sensitive molecular techniques that allow for precise genotyping of HLA antigens. Another report 100 claimed no correlation with HLA phenotype, yet this conclusion may be premature as only 7 patients were examined for HLA and the results were not compared with a control population. Interestingly, 63% of the individuals tested positive for the DQ7 phenotype, the same phenotype seen with increased frequency in a second study. 129 A more recent study reported risk for ALS and survival associated with the HLA DRB5 polymorphism in a Chinese cohort. 130 The same HLA locus was also identified with FTD in a genomewide association study. 131 These associations of specific HLA phenotypes with subsets of ALS patients support a potential autoimmune mechanism in a subset of patients, but additional studies are required.
MHC class I molecules, traditionally thought of in the context of self-vs. non-self recognition by the immune system, play an integral role in the activitydependent structural remodeling of synaptic connections. [132] [133] [134] In ALS, MHC class I molecules may play an important, alternative role in the progression of disease. In SOD1 G93A mice, animals that have greater surface expression of MHC class I molecules on MNs have slower disease progression. 135 Interestingly, cocultures of SOD1 G93A MNs and astrocytes (thought to be toxic to motor neurons) demonstrated a drastic reduction in the surface expression of MHC class I molecules on motor neurons. 80 In additional experiments, it was determined that overexpression of H2-K b fully protected motor neurons from the toxic effect of SOD1 G93A astrocytes in culture. Further, SOD1 mice overexpressing the H2-K b gene had a modest 21-day increase in survival coupled with dramatic increases in ambulatory capacity and motor function, suggesting that class I MHC expression by MNs is a survival-promoting factor in disease. 80 Thus, when examining class I MHC molecules in neurodegenerative diseases such as ALS, it is imperative to recognize that the CNS utilizes these molecules in alternative ways, departing from their traditional use in self-vs. non-self recognition.
CONCLUSIONS
Is there an immune component to ALS pathology? The specific dysfunction and degeneration of MNs provides the basis for the hypothesis that the immune system plays a role in ALS pathogenesis, a theory that is not "new."
25, 136 We have considered some of the critical components of inflammation and immune responses and questioned whether their appearance in disease models or in patient materials corresponds with specific pathological events. At this point in our understanding of the pathogenesis of the disease, we find it challenging to provide a definitive answer to that question. Based on current data, our conclusion is that the immune system does not appear to be involved in ALS. However, there are hints in the literature suggesting this may warrant further investigation. Our goal is to promote discussion on these topics, and to encourage investigators to consider what would be associated with immune involvement and design future studies to include better characterization of immune components, pathological events, and clinical characterization of subjects. Importantly, these types of studies are essential before jumping into a clinical trial where specific patient populations that may be responsive to immune therapies have not been identified. We have reviewed evidence supporting late-stage activation of central immune responses, particularly of microglial activation in response to degenerating MNs, but we should question whether this has any FIGURE 3. Several possibilities are shown for how the immune system may contribute to pathology and MN dysfunction and degeneration in ALS. In this model, NMJ denervation on the periphery is illustrated as site of onset; however, in ALS patients, site of disease onset is variable and may also occur in CNS. Within muscle, tissue macrophages phagocytose debris at a denervated NMJ, including presynaptic elements (green diamond). In ALS with no apparent downstream immune activation, there is normal recognition of self that leads to resolution of inflammation (1) . In ALS presenting with downstream immune activation, intrinsic factors (SOD1, C9ORF72, TDP-43, unknown) and/or an HLA predisposition for autoimmunity contribute to an aberrant phenotype for antigen-presenting cells. Some or all of the following (2-7) occur: Tissue macrophages phagocytize and present presynaptic element "antigen" to T cells (2) . Depending on local cytokine environment, activated T cells further differentiate into T-cell subsets (3) that can further activate tissue macrophages. Activated T cells circulate into lymphoid tissues (e.g., lymph nodes, spleen) promoting further immune system involvement (4). B-cells can also endocytose presynaptic elements as "antigen" and receive a second, extra-follicular activation signal in peripheral circulation, such as circulating LPS, which has been observed in ALS Patients. [133] [134] [135] This can result in antibody production, and/or travel of the B-cell to lymphoid tissue facilitating interaction with T-cells that result in longer lasting antibody production (5) . Consequences of these interactions result in immune components that further the disease pathology.
true impact on disease pathogenesis given that it appears in the later stages. We have examined the role that monocytes and macrophages play in the peripheral pathology of the disease, but it is still inconclusive whether these cell types directly influence progression of the disease. The presence of T cells in the postmortem spinal cords of ALS patients, and the appearance of T lymphocytes in end-stage spinal cords of ALS mice support the role of a terminal immune response at later stages of the disease; however, evidence for these findings is sparse and controversial. In addition, the alternative roles of HLA/MHC used by the CNS add a compounding layer of complexity to the role of immune signaling and regulation in the disease.
Thus, we believe there are data to indicate that individual components of the immune system may be involved in the pathology of MN disease; however, we do not have sufficient understanding as to exactly how and at what point in the pathophysiological cascade this becomes relevant. Thus, we have proposed a model of how the immune system may contribute to disease pathology and progression (Fig. 3) . We urge investigators to characterize the association of local and global immune responses at earlier stages of disease pathology, especially before providing any evidence for the use of immune-altering treatments for ALS. At the bench, we need a consistent characterization of systemic immunoglobulin responses, evaluation of the immune cell subsets and the chemo-and cytokine environments in the peripheral muscles and NMJs, and their responses to ailing MNs, as well as an investigation into the humoral immune response throughout the disease. Investigators should also follow the guidelines proposed to properly power their studies when using the SOD1 mouse model. 137 It is essential that clinicians actively develop and contribute to repositories of different biomaterials, together with clinical data from patients and control subjects. Further, strict and consistent protocols must be established and followed to collect consistent data and sampling across patients, physicians, and institutions, such as the guidelines mandated by the National Institutes of Health for collection of data and biological samples, 138 or those published for specific biorepository design. 139 It is imperative that both basic and clinical investigators establish a greater understanding of the interplay between innate, adaptive, and autoimmunity at the early, middle, and late stages of MN disease progression to design the best treatment trials and provide the best quality of care for patients.
